Sun Pharmaceutical Industries Ltd. | Large-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 137.9B
Gross Profit 109.7B 79.58%
Operating Income 33.7B 24.46%
Net Income 22.9B 16.63%
EPS (Diluted) ₹9.50

Balance Sheet Metrics

Total Assets 921.0B
Total Liabilities 196.1B
Shareholders Equity 724.9B
Debt to Equity 0.27

Cash Flow Metrics

Revenue & Profitability Trend

Sun Pharmaceutical Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i520.4B477.6B432.8B384.3B332.3B
Cost of Goods Sold i122.0B120.7B119.4B103.5B98.9B
Gross Profit i398.4B356.9B313.4B280.7B233.5B
Gross Margin % i76.6%74.7%72.4%73.1%70.3%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i103.0B92.2B80.4B54.7B48.7B
Other Operating Expenses i48.7B46.8B37.4B107.6B33.6B
Total Operating Expenses i151.7B139.0B117.8B162.3B82.2B
Operating Income i125.8B104.7B92.8B81.0B64.1B
Operating Margin % i24.2%21.9%21.4%21.1%19.3%
Non-Operating Items
Interest Income i12.3B10.2B3.8B5.5B2.1B
Interest Expense i2.3B2.4B1.7B1.3B1.4B
Other Non-Operating Income-----
Pre-tax Income i137.5B110.9B94.1B44.8B28.0B
Income Tax i27.7B14.4B8.5B10.8B5.1B
Effective Tax Rate % i20.2%13.0%9.0%24.0%18.4%
Net Income i109.6B96.1B85.1B33.9B22.7B
Net Margin % i21.1%20.1%19.7%8.8%6.8%
Key Metrics
EBITDA i167.3B142.9B122.9B113.2B90.5B
EPS (Basic) i₹45.60₹39.90₹35.30₹13.60₹12.10
EPS (Diluted) i₹45.60₹39.90₹35.30₹13.60₹12.10
Basic Shares Outstanding i23993349702399334970239933497024064191182399334970
Diluted Shares Outstanding i23993349702399334970239933497024064191182399334970

Income Statement Trend

Sun Pharmaceutical Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i102.7B92.9B46.2B45.1B62.7B
Short-term Investments i160.5B100.4B107.9B81.5B32.9B
Accounts Receivable i130.5B112.5B114.4B105.9B90.6B
Inventory i102.4B98.7B105.1B90.0B90.0B
Other Current Assets733.5M646.7M862.5M540.9M508.2M
Total Current Assets i526.2B434.7B398.8B350.1B304.4B
Non-Current Assets
Property, Plant & Equipment i100.4B101.9B103.9B103.7B102.3B
Goodwill i269.0B258.6B260.4B191.3B182.4B
Intangible Assets i90.2B86.7B93.3B60.3B56.6B
Long-term Investments-0100.0K5.5M2.0M
Other Non-Current Assets5.4B4.7B51.6B-1.0M5.4B
Total Non-Current Assets i394.8B419.9B408.6B347.8B372.2B
Total Assets i921.0B854.6B807.4B698.0B676.7B
Liabilities
Current Liabilities
Accounts Payable i61.8B56.5B56.8B44.8B39.7B
Short-term Debt i20.0B29.7B63.3B8.1B29.7B
Current Portion of Long-term Debt-----
Other Current Liabilities10.4B9.6B4.9B5.1B5.1B
Total Current Liabilities i181.9B169.8B199.1B172.0B161.5B
Non-Current Liabilities
Long-term Debt i3.6B3.0B5.6B4.8B9.0B
Deferred Tax Liabilities i1.9B1.6B316.9M318.6M445.1M
Other Non-Current Liabilities191.8M112.0M129.5M157.0M333.8M
Total Non-Current Liabilities i14.2B13.7B15.2B15.3B20.4B
Total Liabilities i196.1B183.6B214.3B187.3B181.9B
Equity
Common Stock i2.4B2.4B2.4B2.4B2.4B
Retained Earnings i578.6B501.5B436.1B376.5B366.0B
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i724.9B671.1B593.2B510.7B494.8B
Key Metrics
Total Debt i23.6B32.7B68.9B12.9B38.7B
Working Capital i344.3B264.9B199.8B178.1B143.0B

Balance Sheet Composition

Sun Pharmaceutical Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i137.5B110.9B94.1B44.8B28.0B
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i-16.6B8.1B-30.4B-33.5B16.3B
Operating Cash Flow i110.8B110.8B61.4B6.9B43.5B
Investing Activities
Capital Expenditures i-20.7B-21.7B-20.6B-14.3B-10.7B
Acquisitions i-3.2B-2.3B-48.4B-7.2B-616.0M
Investment Purchases i-344.7B-305.7B-225.3B-246.6B-188.2B
Investment Sales i306.5B315.9B210.5B208.7B202.0B
Investing Cash Flow i-62.0B-13.8B-83.9B-59.4B2.4B
Financing Activities
Share Repurchases i-29.0B-773.9M0-1.9B-1.9B
Dividends Paid i-36.1B-29.0B-25.2B-21.6B-15.6B
Debt Issuance i33.6B45.7B81.6B16.6B66.0B
Debt Repayment i-43.4B-81.1B-29.0B-44.0B-108.0B
Financing Cash Flow i-75.4B-63.7B26.1B-49.8B-56.9B
Free Cash Flow i119.4B99.3B28.7B74.9B50.0B
Net Change in Cash i-26.6B33.4B3.6B-102.3B-11.1B

Cash Flow Trend

Sun Pharmaceutical Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 36.63
Forward P/E 48.56
Price to Book 5.27
Price to Sales 7.13
PEG Ratio 48.56

Profitability Ratios

Profit Margin 19.29%
Operating Margin 24.34%
Return on Equity 15.08%
Return on Assets 11.87%

Financial Health

Current Ratio 2.89
Debt to Equity 3.26
Beta 0.31

Per Share Data

EPS (TTM) ₹43.32
Book Value per Share ₹300.99
Revenue per Share ₹224.24

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
sunpharma3.8T36.635.2715.08%19.29%3.26
Divi's Laboratories 1.6T68.0310.4914.64%23.89%0.03
Torrent 1.2T60.5715.9325.18%16.92%42.81
Cipla 1.2T22.273.8516.85%19.62%1.40
Mankind Pharma 1.0T53.197.1013.67%14.66%58.43
Dr. Reddy's 1.0T17.792.8817.71%16.99%13.75

Financial data is updated regularly. All figures are in the company's reporting currency.